Trial Outcomes & Findings for Study of WVE-003 in Patients With Huntington's Disease (NCT NCT05032196)

Last Updated: 2025-08-12

Results Overview

The primary outcome for this study was safety and is reported as the proportion of patients with TEAEs related to study drug.

Recruitment status

COMPLETED

Study phase

PHASE1/PHASE2

Target enrollment

47 participants

Primary outcome timeframe

Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2)

Results posted on

2025-08-12

Participant Flow

Participant milestones

Participant milestones
Measure	SAD: Pooled Placebo SAD: Single dose of placebo.	SAD: 30mg WVE-003* SAD: Single ascending dose of 30mg WVE-003. \*	SAD: 60mg WVE-003* SAD: Single ascending dose of 60mg WVE-003. \*	SAD: 90mg WVE-003 SAD: Single ascending dose of 90mg WVE-003.	MD: Placebo MD: 3 doses of placebo Q8W. 7 Pts from Period 1 rolled over into Period 2.	MD: 30mg WVE-003 MD: 3 doses of 30mg WVE-003 Q8W. 16 Pts rolled over from Period 1 into Period 2.
Period 1 (Single Ascending Dose) STARTED	16	12	11	8	0	0
Period 1 (Single Ascending Dose) COMPLETED	16	11	11	7	0	0
Period 1 (Single Ascending Dose) NOT COMPLETED	0	1	0	1	0	0
Period 2 (Multidose) STARTED	0	0	0	0	7	16
Period 2 (Multidose) Treated	0	0	0	0	7	16
Period 2 (Multidose) COMPLETED	0	0	0	0	6	16
Period 2 (Multidose) NOT COMPLETED	0	0	0	0	1	0

Reasons for withdrawal

Reasons for withdrawal
Measure	SAD: 30mg WVE-003* SAD: Single ascending dose of 30mg WVE-003. \*	SAD: 90mg WVE-003 SAD: Single ascending dose of 90mg WVE-003.	MD: Placebo MD: 3 doses of placebo Q8W. 7 Pts from Period 1 rolled over into Period 2.
Period 1 (Single Ascending Dose) Withdrawal by Subject	1	0	0
Period 1 (Single Ascending Dose) Adverse Event	0	1	0
Period 2 (Multidose) Physician Decision	0	0	1

Baseline Characteristics

47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	SAD: Pooled Placebo n=16 Participants Placebo SAD: Pooled Placebo: Single dose of placebo	SAD: 30mg WVE-003 n=13 Participants Single Ascending Dose - 30mg WVE-003 SAD: 30mg WVE-003: Single ascending dose of 30mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)	SAD: 60mg WVE-003 n=10 Participants Single Ascending Dose - 60mg WVE-003 SAD: 60mg WVE-003: Single ascending dose of 60mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)	SAD: 90mg WVE-003 n=8 Participants Single Ascending Dose - 90mg WVE-003 SAD: 90mg WVE-003: Single ascending dose of 90mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)	MD: Placebo n=7 Participants Placebo MD: Placebo: Three doses of placebo Q8WK	MD: 30mg WVE-003 n=16 Participants Multiple Dose - 30mg WVE-003 MD: 30mg WVE-003: Three doses of 30mg WVE-003 Q8WK an allele-selective stereopure antisense oligonucleotide (ASO	Total n=70 Participants Total of all reporting groups
Age, Continuous Period 1	45.5 years STANDARD_DEVIATION 7.4 • n=16 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	47.8 years STANDARD_DEVIATION 9.2 • n=13 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	43.9 years STANDARD_DEVIATION 8.6 • n=10 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	49.6 years STANDARD_DEVIATION 5.3 • n=8 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	—	—	46.5 years STANDARD_DEVIATION 7.9 • n=47 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.
Age, Continuous Period 2	—	—	—	—	45.6 years STANDARD_DEVIATION 8.3 • n=7 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	47.8 years STANDARD_DEVIATION 8.3 • n=16 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	47.1 years STANDARD_DEVIATION 8.2 • n=23 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.
Sex: Female, Male Period 1 · Female	6 Participants n=16 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	6 Participants n=13 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	3 Participants n=10 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	3 Participants n=8 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	—	—	18 Participants n=47 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.
Sex: Female, Male Period 1 · Male	10 Participants n=16 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	7 Participants n=13 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	7 Participants n=10 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	5 Participants n=8 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	—	—	29 Participants n=47 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.
Sex: Female, Male Period 2 · Female	—	—	—	—	2 Participants n=7 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	5 Participants n=16 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	7 Participants n=23 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.
Sex: Female, Male Period 2 · Male	—	—	—	—	5 Participants n=7 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	11 Participants n=16 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	16 Participants n=23 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.
Ethnicity (NIH/OMB) Period 1 · Hispanic or Latino	1 Participants n=16 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=13 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=10 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=8 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	—	—	1 Participants n=47 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.
Ethnicity (NIH/OMB) Period 1 · Not Hispanic or Latino	15 Participants n=16 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	13 Participants n=13 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	10 Participants n=10 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	8 Participants n=8 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	—	—	46 Participants n=47 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.
Ethnicity (NIH/OMB) Period 1 · Unknown or Not Reported	0 Participants n=16 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=13 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=10 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=8 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	—	—	0 Participants n=47 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.
Ethnicity (NIH/OMB) Period 2 · Hispanic or Latino	—	—	—	—	1 Participants n=7 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=16 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	1 Participants n=23 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.
Ethnicity (NIH/OMB) Period 2 · Not Hispanic or Latino	—	—	—	—	6 Participants n=7 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	16 Participants n=16 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	22 Participants n=23 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.
Ethnicity (NIH/OMB) Period 2 · Unknown or Not Reported	—	—	—	—	0 Participants n=7 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=16 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=23 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.
Race (NIH/OMB) Period 1 · American Indian or Alaska Native	0 Participants n=16 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=13 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=10 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=8 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	—	—	0 Participants n=47 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.
Race (NIH/OMB) Period 1 · Asian	0 Participants n=16 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=13 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=10 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=8 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	—	—	0 Participants n=47 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.
Race (NIH/OMB) Period 1 · Native Hawaiian or Other Pacific Islander	0 Participants n=16 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=13 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=10 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=8 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	—	—	0 Participants n=47 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.
Race (NIH/OMB) Period 1 · Black or African American	0 Participants n=16 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=13 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=10 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=8 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	—	—	0 Participants n=47 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.
Race (NIH/OMB) Period 1 · White	16 Participants n=16 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	13 Participants n=13 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	10 Participants n=10 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	8 Participants n=8 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	—	—	47 Participants n=47 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.
Race (NIH/OMB) Period 1 · More than one race	0 Participants n=16 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=13 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=10 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=8 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	—	—	0 Participants n=47 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.
Race (NIH/OMB) Period 1 · Unknown or Not Reported	0 Participants n=16 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=13 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=10 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=8 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	—	—	0 Participants n=47 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.
Race (NIH/OMB) Period 2 · American Indian or Alaska Native	—	—	—	—	0 Participants n=7 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=16 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=23 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.
Race (NIH/OMB) Period 2 · Asian	—	—	—	—	0 Participants n=7 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=16 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=23 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.
Race (NIH/OMB) Period 2 · Native Hawaiian or Other Pacific Islander	—	—	—	—	0 Participants n=7 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=16 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=23 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.
Race (NIH/OMB) Period 2 · Black or African American	—	—	—	—	7 Participants n=7 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	16 Participants n=16 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	23 Participants n=23 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.
Race (NIH/OMB) Period 2 · White	—	—	—	—	0 Participants n=7 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=16 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=23 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.
Race (NIH/OMB) Period 2 · More than one race	—	—	—	—	0 Participants n=7 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=16 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=23 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.
Race (NIH/OMB) Period 2 · Unknown or Not Reported	—	—	—	—	0 Participants n=7 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=16 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.	0 Participants n=23 Participants • 47 participants were enrolled into Period 1, and of those 23 participants were rolled over into Period 2.

PRIMARY outcome

Timeframe: Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2)

The primary outcome for this study was safety and is reported as the proportion of patients with TEAEs related to study drug.

Outcome measures

Outcome measures
Measure	SAD: Pooled Placebo n=16 Participants Placebo SAD: Pooled Placebo: Single dose of placebo	SAD: 30mg WVE-003 n=13 Participants Single Ascending Dose - 30mg WVE-003 SAD: 30mg WVE-003: Single ascending dose of 30mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)	SAD: 60mg WVE-003 n=10 Participants Single Ascending Dose - 60mg WVE-003 SAD: 60mg WVE-003: Single ascending dose of 60mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)	SAD: 90mg WVE-003 n=8 Participants Single Ascending Dose - 90mg WVE-003 SAD: 90mg WVE-003: Single ascending dose of 90mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)	MD: Placebo n=7 Participants Placebo MD: Placebo: Three doses of placebo Q8WK	MD: 30mg WVE-003 n=16 Participants Multiple Dose - 30mg WVE-003 MD: 30mg WVE-003: Three doses of 30mg WVE-003 Q8WK an allele-selective stereopure antisense oligonucleotide (ASO
Safety: Proportion of Patients With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug	2 Participants	1 Participants	3 Participants	3 Participants	0 Participants	8 Participants

SECONDARY outcome

Timeframe: Day 1 (single ascending dose Period 1); Day 1 and Day 113 (multi dose Period 2)

Population: Please note that the PK analysis only includes participants treated with WVE-003 (all placebo participants have been set as '0').

Parameter analyzed: AUC0-6 = area under the concentration-time curve from time 0 to 6 hrs

Outcome measures

Outcome measures
Measure	SAD: Pooled Placebo n=13 Participants Placebo SAD: Pooled Placebo: Single dose of placebo	SAD: 30mg WVE-003 n=10 Participants Single Ascending Dose - 30mg WVE-003 SAD: 30mg WVE-003: Single ascending dose of 30mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)	SAD: 60mg WVE-003 n=8 Participants Single Ascending Dose - 60mg WVE-003 SAD: 60mg WVE-003: Single ascending dose of 60mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)	SAD: 90mg WVE-003 n=16 Participants Single Ascending Dose - 90mg WVE-003 SAD: 90mg WVE-003: Single ascending dose of 90mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)	MD: Placebo Placebo MD: Placebo: Three doses of placebo Q8WK	MD: 30mg WVE-003 Multiple Dose - 30mg WVE-003 MD: 30mg WVE-003: Three doses of 30mg WVE-003 Q8WK an allele-selective stereopure antisense oligonucleotide (ASO
Pharmacokinetics of WVE-003 in Plasma D1: AUC 0-6 (hr*ng/mL)	1000 AUC 0-6 (hr*ng/mL) Standard Deviation 702	2310 AUC 0-6 (hr*ng/mL) Standard Deviation 3090	3890 AUC 0-6 (hr*ng/mL) Standard Deviation 2900	822 AUC 0-6 (hr*ng/mL) Standard Deviation 409	—	—
Pharmacokinetics of WVE-003 in Plasma D113: AUC 0-6 (hr*ng/mL)	—	—	—	698 AUC 0-6 (hr*ng/mL) Standard Deviation 432	—	—

SECONDARY outcome

Timeframe: Day 1 (single ascending dose Period 1); Day 1 and Day 113 (multi dose Period 2)

Population: Please note that the PK analysis only includes participants treated with WVE-003 (all placebo participants have been set as '0').

Parameter analyzed: Cmax = maximum observed concentration.

Outcome measures

Outcome measures
Measure	SAD: Pooled Placebo n=13 Participants Placebo SAD: Pooled Placebo: Single dose of placebo	SAD: 30mg WVE-003 n=10 Participants Single Ascending Dose - 30mg WVE-003 SAD: 30mg WVE-003: Single ascending dose of 30mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)	SAD: 60mg WVE-003 n=8 Participants Single Ascending Dose - 60mg WVE-003 SAD: 60mg WVE-003: Single ascending dose of 60mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)	SAD: 90mg WVE-003 n=16 Participants Single Ascending Dose - 90mg WVE-003 SAD: 90mg WVE-003: Single ascending dose of 90mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)	MD: Placebo Placebo MD: Placebo: Three doses of placebo Q8WK	MD: 30mg WVE-003 Multiple Dose - 30mg WVE-003 MD: 30mg WVE-003: Three doses of 30mg WVE-003 Q8WK an allele-selective stereopure antisense oligonucleotide (ASO
Pharmacokinetics of WVE-003 in Plasma D1: Cmax (ng/mL)	240 Cmax (ng/mL) Standard Deviation 168	601 Cmax (ng/mL) Standard Deviation 774	1061 Cmax (ng/mL) Standard Deviation 942	186 Cmax (ng/mL) Standard Deviation 106	—	—
Pharmacokinetics of WVE-003 in Plasma D113: Cmax (ng/mL)	—	—	—	157 Cmax (ng/mL) Standard Deviation 97.3	—	—

SECONDARY outcome

Timeframe: 28 days post-dose during Period 1 (P1:Day29); 28 days post last dose during Period 2 (P2: Day141)

Population: Please note that the PK analysis only includes participants treated with WVE-003 (all placebo participants have been set as '0').

WVE-003 concentration in cerebrospinal fluid (CSF) is reported in ng/mL.

Outcome measures

Outcome measures
Measure	SAD: Pooled Placebo n=13 Participants Placebo SAD: Pooled Placebo: Single dose of placebo	SAD: 30mg WVE-003 n=10 Participants Single Ascending Dose - 30mg WVE-003 SAD: 30mg WVE-003: Single ascending dose of 30mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)	SAD: 60mg WVE-003 n=8 Participants Single Ascending Dose - 60mg WVE-003 SAD: 60mg WVE-003: Single ascending dose of 60mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)	SAD: 90mg WVE-003 n=16 Participants Single Ascending Dose - 90mg WVE-003 SAD: 90mg WVE-003: Single ascending dose of 90mg WVE-003, an allele-selective stereopure antisense oligonucleotide (ASO)	MD: Placebo Placebo MD: Placebo: Three doses of placebo Q8WK	MD: 30mg WVE-003 Multiple Dose - 30mg WVE-003 MD: 30mg WVE-003: Three doses of 30mg WVE-003 Q8WK an allele-selective stereopure antisense oligonucleotide (ASO
Concentration of WVE-003 in Cerebrospinal Fluid (CSF)	3.6405 ng/mL Standard Deviation 1.6133	5.5346 ng/mL Standard Deviation 2.8402	7.0983 ng/mL Standard Deviation 3.1335	4.2903 ng/mL Standard Deviation 1.9722	—	—

Adverse Events

SAD: Pooled Placebo

Serious events: 1 serious events

Other events: 13 other events

Deaths: 0 deaths

SAD: 30mg WVE-003

Serious events: 0 serious events

Other events: 9 other events

Deaths: 0 deaths

SAD: 60mg WVE-003

Serious events: 1 serious events

Other events: 8 other events

Deaths: 0 deaths

SAD: 90mg WVE-003

Serious events: 0 serious events

Other events: 8 other events

Deaths: 0 deaths

MD: Placebo

Serious events: 0 serious events

Other events: 7 other events

Deaths: 0 deaths

MD: 30mg WVE-003

Serious events: 0 serious events

Other events: 13 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	SAD: Pooled Placebo n=16 participants at risk Placebo SAD: Pooled Placebo: Single dose of placebo	SAD: 30mg WVE-003 n=13 participants at risk Single Ascending Dose - 30mg WVE-003 SAD: 30mg WVE-003: Single ascending dose of 30mg WVE-003, a stereopure antisense oligonucleotide (ASO)	SAD: 60mg WVE-003 n=10 participants at risk Single Ascending Dose - 60mg WVE-003 SAD: 60mg WVE-003: Single ascending dose of 60mg WVE-003, a stereopure antisense oligonucleotide (ASO)	SAD: 90mg WVE-003 n=8 participants at risk Single Ascending Dose - 90mg WVE-003 SAD: 90mg WVE-003: Single ascending dose of 90mg WVE-003, a stereopure antisense oligonucleotide (ASO)	MD: Placebo n=7 participants at risk Placebo MD: Placebo: Three doses of placebo Q8WK	MD: 30mg WVE-003 n=16 participants at risk Multiple Dose - 30mg WVE-003 MD: 30mg WVE-003: Three doses of 30mg WVE-003 Q8WK a stereopure antisense oligonucleotide (ASO
Injury, poisoning and procedural complications Post lumbar puncture syndrome	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Nervous system disorders Ataxia	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	10.0% 1/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.

Other adverse events

Other adverse events
Measure	SAD: Pooled Placebo n=16 participants at risk Placebo SAD: Pooled Placebo: Single dose of placebo	SAD: 30mg WVE-003 n=13 participants at risk Single Ascending Dose - 30mg WVE-003 SAD: 30mg WVE-003: Single ascending dose of 30mg WVE-003, a stereopure antisense oligonucleotide (ASO)	SAD: 60mg WVE-003 n=10 participants at risk Single Ascending Dose - 60mg WVE-003 SAD: 60mg WVE-003: Single ascending dose of 60mg WVE-003, a stereopure antisense oligonucleotide (ASO)	SAD: 90mg WVE-003 n=8 participants at risk Single Ascending Dose - 90mg WVE-003 SAD: 90mg WVE-003: Single ascending dose of 90mg WVE-003, a stereopure antisense oligonucleotide (ASO)	MD: Placebo n=7 participants at risk Placebo MD: Placebo: Three doses of placebo Q8WK	MD: 30mg WVE-003 n=16 participants at risk Multiple Dose - 30mg WVE-003 MD: 30mg WVE-003: Three doses of 30mg WVE-003 Q8WK a stereopure antisense oligonucleotide (ASO
Psychiatric disorders Irritability	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 1/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Psychiatric disorders Anxiety	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Investigations CSF red blood cell count positive	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	7.7% 1/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Blood and lymphatic system disorders Eosinophilia	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Gastrointestinal disorders Abdominal pain	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Gastrointestinal disorders Diarrhoea	12.5% 2/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Gastrointestinal disorders Toothache	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
General disorders Fatigue	12.5% 2/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	15.4% 2/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 1/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	14.3% 1/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 2/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
General disorders Pain	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 1/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 2/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
General disorders Non-cardiac chest pain	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Infections and infestations Nasopharyngitis	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	14.3% 1/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 2/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Infections and infestations Influenza	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	14.3% 1/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Infections and infestations Upper respiratory tract infection	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	14.3% 1/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Injury, poisoning and procedural complications Fall	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	10.0% 1/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	37.5% 3/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	28.6% 2/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 2/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Injury, poisoning and procedural complications Skin laceration	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	10.0% 1/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 2/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Injury, poisoning and procedural complications Contusion	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	10.0% 1/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 1/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	14.3% 1/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Injury, poisoning and procedural complications Ligament sprain	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Injury, poisoning and procedural complications Post lumbar puncture syndrome	12.5% 2/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	7.7% 1/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	10.0% 1/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	25.0% 2/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	14.3% 1/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Injury, poisoning and procedural complications Procedural pain	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	7.7% 1/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	25.0% 2/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	14.3% 1/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Investigations CSF white blood cell count increased	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	7.7% 1/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	25.0% 2/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 2/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Investigations Blood creatine phosphokinase increased	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 1/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Investigations CSF protein increased	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	15.4% 2/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	10.0% 1/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	25.0% 2/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	14.3% 1/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Musculoskeletal and connective tissue disorders Back pain	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	23.1% 3/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	20.0% 2/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 1/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	28.6% 2/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Nervous system disorders Headache	37.5% 6/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	30.8% 4/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	20.0% 2/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	50.0% 4/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	42.9% 3/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	25.0% 4/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Nervous system disorders Balance disorder	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	10.0% 1/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 1/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Nervous system disorders Coordination abnormal	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Nervous system disorders Dizziness	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	7.7% 1/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Nervous system disorders Dyskinesia	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Nervous system disorders Hyperaesthesia	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Nervous system disorders Hyporeflexia	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 1/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Nervous system disorders Paraesthesia	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Nervous system disorders Paresis	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Nervous system disorders Pleocytosis	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	10.0% 1/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Nervous system disorders Presyncope	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	7.7% 1/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Nervous system disorders Intracranial hypotension	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	14.3% 1/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Psychiatric disorders Attention deficit hyperactivity disorder	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Psychiatric disorders Depression	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 1/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	14.3% 1/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Psychiatric disorders Sleep disorder	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	14.3% 1/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Reproductive system and breast disorders Amenorrhoea	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Skin and subcutaneous tissue disorders Eczema	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Cardiac disorders Tachycardia	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Eye disorders Eye pain	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	7.7% 1/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Gastrointestinal disorders Nausea	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	7.7% 1/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	25.0% 2/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Gastrointestinal disorders Constipation	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 1/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Gastrointestinal disorders Dental caries	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	10.0% 1/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Gastrointestinal disorders Vomiting	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 1/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
General disorders Influenza like illness	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	7.7% 1/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
General disorders Pyrexia	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 1/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
General disorders Vessel puncture site haematoma	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 1/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
General disorders Puncture site pain	12.5% 2/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Infections and infestations COVID-19	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	10.0% 1/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Infections and infestations Urinary tract infection	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	10.0% 1/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Infections and infestations Infected seroma	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Injury, poisoning and procedural complications Skin abrasion	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	10.0% 1/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 1/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Injury, poisoning and procedural complications Concussion	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 1/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Injury, poisoning and procedural complications Head injury	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 1/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Injury, poisoning and procedural complications Injury	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 1/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Injury, poisoning and procedural complications Procedural complication	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 1/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Injury, poisoning and procedural complications Upper limb fracture	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 1/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Injury, poisoning and procedural complications Eye injury	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Injury, poisoning and procedural complications Limb injury	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Injury, poisoning and procedural complications Lip injury	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Injury, poisoning and procedural complications Road traffic accident	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Investigations C-reactive protein increased	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	10.0% 1/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 1/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	15.4% 2/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	10.0% 1/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Musculoskeletal and connective tissue disorders Muscle contracture	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Nervous system disorders Sciatica	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	7.7% 1/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Nervous system disorders Tension headache	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 1/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Psychiatric disorders Depressed mood	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	7.7% 1/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Psychiatric disorders Disorientation	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 1/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Psychiatric disorders Compulsions	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Psychiatric disorders Insomnia	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Reproductive system and breast disorders Intermenstrual bleeding	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	7.7% 1/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Respiratory, thoracic and mediastinal disorders Cough	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Respiratory, thoracic and mediastinal disorders Nasal congestion	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Skin and subcutaneous tissue disorders Rash	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	10.0% 1/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Skin and subcutaneous tissue disorders Rash erythematous	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	10.0% 1/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Skin and subcutaneous tissue disorders Dermatitis contact	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Skin and subcutaneous tissue disorders Skin irritation	6.2% 1/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Vascular disorders Hypotension	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	10.0% 1/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 1/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.
Vascular disorders Haematoma	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/13 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/10 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	12.5% 1/8 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/7 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.	0.00% 0/16 • Day 1 through Week 24 (single ascending dose Period 1); Day 1 through Week 28 (multi dose Period 2) This study protocol collected all treatment-emergent adverse events and serious adverse events, whether they were treatment related or not. 5 months after a patient completed their final safety visit, an SAE was reported that sponsor assessed to be not-related to WVE-003.

Additional Information

Medical Director, MD

Wave Life Sciences USA, Inc

Phone: +1 617-949-2900

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place